{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-21-024928","form_type":"8-K","ticker":"CSBR","cik":"0000771856","company_name":"CHAMPIONS ONCOLOGY, INC.","filed_at":"2021-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.553227+00:00","generated_at":"2026-06-28T01:53:36.816315+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Champions Oncology reports record Q2 revenue $11.8M, up 17% YoY; operating income $263K","bullets":["Record quarterly revenue of $11.8M, up 17% from $10.1M year ago.","GAAP operating income of $263K vs. $7K a year ago; non-GAAP operating income $743K vs. $399K.","Gross margin improved to 52.4% from 44.2% due to reduced outsourcing.","Cash position $4.8M, no debt; net cash from ops $1.2M in quarter.","R&D investment increased 39.3% to $2.3M for therapeutic target discovery."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-21-024928","json":"https://secwatch.observer/filing/0001628280-21-024928.json","markdown":"https://secwatch.observer/filing/0001628280-21-024928.md","text":"https://secwatch.observer/filing/0001628280-21-024928.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/771856/000162828021024928/0001628280-21-024928-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/771856/000162828021024928/csbr-20211213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T01:53:36.816315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}